Zila's branded ingredient Ester-E will roll out to national retailers in the coming weeks, with consumer advertising beginning this month and radio promotions from national spokesperson Larry King. In the firm's fiscal fourth quarter, Zila "essentially sold all of the Ester-E that we could manufacture," CEO Doug Burkett said August 2. In fiscal 2005, the firm will add a second production line and double its 2004 marketing investment in the Ester brand with the goals of rapidly growing Ester-E and maintaining double-digit sales growth for Ester-C. In January, Zila said Ester-E could top $26 mil. in annual revenues (1"The Tan Sheet" Jan. 5, 2004, p. 13)...
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
If approved, Sanofi’s acoziborole could become the first single-dose oral treatment for sleeping sickness.
Mexico’s drugs regulator will be able to grant quicker drug approvals based on decisions issued by World Health Organization listed authorities and founding ICH members.
Biogen has U-turned on its original decision not to file Qalsody for marketing approval in the UK for treating certain patients with amyotrophic lateral sclerosis. The move appears to have been triggered by a change in the reimbursement pathway agreed for the product.
